Ardent Scientist, Savvy Advocate

On most days, Francis S. Collins, director of the National Human Genome Research Institute, coordinates with genome centers around the world and evaluates ethical, legal, and social implications of the project that made him famous. But Collins reserves this day in late July for the passion that brought him to the institute in the first place: research to identify which of the human body's 35,000 genes causes Type 2 diabetes. Assembled around a table in the vaccine center of the National Institut

Written byDana Wilkie
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

In this room of simple chairs and bare walls, Francis Collins--trailblazing scientist, cartographer of the human genome--meets Francis Collins, explorer who knows he still lacks much knowledge. You can almost see the lanky teen of 35 years ago who adored chemistry and physics for their logic and order but hated biology for its unpredictability. Odd, then, that the accomplishment for which Collins is globally known, the Human Genome Project, has so much to do with the science of life. A scant seven months ago, Collins and J. Craig Venter, the rival scientist who led a private-sector effort at the same time Collins was leading a public consortium effort, announced they had all but finished mapping and sequencing the human genome,1 opening up one world of medical and genetic possibilities and another world of ethical dilemmas. Francis Collins, who gained recognition from his work on the Human Genome Project, believes that ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies